Translate Please note that some translations using Google Translate may not be accurately represented and downloaded documents cannot be translated. Dana-Farber/Boston Children’s assumes no liability for inaccuracies that may result from using this third-party tool, which is for website translation and not clinical interactions. You may request a medical interpreter for a discussion about your care.
Displaying 1-10 of 73 results matching:
David Williams, MD, has been awarded the Henry M. Stratton Medal for clinical science by the American Society of Hematology, one of the highest distinctions for excellence in the hematology field.
She will also serve as Associate Chief of the Division of Hematology/Oncology at Boston Children’s Hospital
Dana-Farber/Boston Children’s is honored to have 11 faculty members named part of Boston Magazine’s "Top Doctors" for 2025.
U.S. News & World Report has again recognized Dana-Farber/Boston Children's Cancer and Blood Disorders Center as the #2 pediatric cancer program in the nation in its 2024-25 Best Children's Hospitals report.
Dana-Farber/Boston Children’s Cancer and Blood Disorder Center is happy to announce three research fellows have been named as part of the Inaugural class of Damon Runyon–St. Jude Pediatric Cancer Research Fellows.
Lisa Diller, MD, Chief Medical Officer at the Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, has been named an Innovator in Healthcare for Research by the Boston Business Journal.
U.S. News & World Report has named Dana-Farber/Boston Children's Cancer and Blood Disorders Center the #2 pediatric program in the nation in its 2023-24 Best Children's Hospitals report.
Boston magazine has named numerous Dana-Farber/Boston Children’s Cancer and Blood Disorders Center faculty members to its annual "Top Doctors" guide.
After an extensive national search, it is with great pleasure that Dana-Farber/Boston Children's Cancer and Blood Disorders Center introduces Abby R. Rosenberg, MD, MS, MA, as the new Chief of Pediatric Palliative Care at Dana-Farber Cancer Institute and Director of Palliative Care at Boston Children’s Hospital.
Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a better understanding of what these tumors look like and can work towards developing new treatment approaches.